.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Farmers Insurance
Federal Trade Commission
Express Scripts
Merck
Dow
Accenture
Chubb
Teva

Generated: June 26, 2017

DrugPatentWatch Database Preview

INVOKAMET Drug Profile

« Back to Dashboard

What is the patent landscape for Invokamet, and when can generic versions of Invokamet launch?

Invokamet is a drug marketed by Janssen Pharms and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in forty-two countries.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

Summary for Tradename: INVOKAMET

Patents:5
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:INVOKAMET at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-002Sep 20, 2016RXYesNo7,943,582► SubscribeYY ► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-004Aug 8, 2014RXYesYes7,943,582► SubscribeYY ► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo8,222,219► Subscribe ► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-004Sep 20, 2016RXYesYes► Subscribe► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo6,723,340► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INVOKAMET

Drugname Dosage Strength RLD Submissiondate
canagliflozin andmetforminhydrochlorideTablets50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mgInvokamet3/29/2017

Non-Orange Book Patents for Tradename: INVOKAMET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,935,674Indole derivatives► Subscribe
8,202,984Glucopyranoside compound► Subscribe
7,129,220Substituted indole-O-glucosides► Subscribe
7,816,330Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
7,511,020Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: INVOKAMET

Country Document Number Estimated Expiration
South Korea101259198► Subscribe
Japan5225679► Subscribe
Canada2595218► Subscribe
New Zealand545304► Subscribe
TaiwanI377209► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: INVOKAMET

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131119
2014 00024Denmark► SubscribePRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
14/029Ireland► SubscribePRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
2014008,C1651658Lithuania► SubscribePRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
0140011 00102Estonia► SubscribePRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Moodys
Cantor Fitzgerald
Dow
Daiichi Sankyo
McKinsey
Merck
Federal Trade Commission
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot